Literature DB >> 24637340

The R.E.N.A.L. nephrometric nomogram cannot accurately predict malignancy or aggressiveness of small renal masses amenable to partial nephrectomy.

Alessandro Antonelli1, Maria Furlan2, Marco Sandri3, Andrea Minervini4, Luca Cindolo5, Paolo Parma6, Stefano Zaramella7, Angelo Porreca8, Gianni Vittori4, Alessandro Samuelli6, Donato Dente8, Francesco Berardinelli5, Maria Rosaria Raspollini4, Sergio Serni4, Marco Carini4, Carlo Terrone7, Luigi Schips5, Claudio Simeone2.   

Abstract

INTRODUCTION/
BACKGROUND: The prediction of histology of SRM could be essential for their management. The RNN is a statistical tool designed to predict malignancy or high grading of enhancing renal masses. In this study we aimed to perform an external validation of the RNN in a cohort of patients who received a PN for SRM.
MATERIALS AND METHODS: This was a multicentric study in which the data of 506 consecutive patients who received a PN for cT1a SRM between January 2010 and January 2013 were analyzed. For each patient, the probabilities of malignancy and aggressiveness were estimated preoperatively using the RNN. The performance of the RNN was evaluated according to receiver operating characteristic (ROC) curve, calibration plot, and decision curve analyses.
RESULTS: The area under the ROC curve for malignancy was 0.57 (95% confidence interval [CI], 0.51-0.63; P = .031). The calibration plot showed that the predicted probability of malignancy had a bad concordance with observed frequency (Brier score = 0.17; 95% CI, 0.15-0.19). Decision curve analysis confirmed a poor clinical benefit from use of the system. The estimated area under the ROC curve for high-grade prediction was 0.57 (95% CI, 0.49-0.66; P = .064). The calibration plot evidenced a bad concordance (Brier score = 0.15; 95% CI, 0.13-0.17). Decision curve analysis showed the lack of a remarkable clinical usefulness of the RNN when predicting aggressiveness.
CONCLUSIONS: The RNN cannot accurately predict histology in the setting of cT1a SRM amenable to PN.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  High-grade; Malignancy; Partial nephrectomy; RENAL nephrometry nomogram; Small renal mass

Mesh:

Year:  2014        PMID: 24637340     DOI: 10.1016/j.clgc.2014.02.003

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  5 in total

1.  External validation of a nomogram including the computed tomography imaging score to predict indolent renal masses.

Authors:  X Chen; B Wan; D Yang; H Zhao; W Tan
Journal:  Int Urol Nephrol       Date:  2017-04-17       Impact factor: 2.370

2.  Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis.

Authors:  Mark W Ball; Michael A Gorin; Sam B Bhayani; Craig G Rogers; Michael D Stifelman; Jihad H Kaouk; Homayoun Zargar; Susan Marshall; Jeffrey A Larson; Haider M Rahbar; Bruce J Trock; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Urol Oncol       Date:  2014-12-11       Impact factor: 3.498

3.  Pathological diagnostic nomograms for predicting malignant histology and unfavorable pathology in patients with endophytic renal tumor.

Authors:  Xinxi Deng; Xiaoqiang Liu; Bing Hu; Ming Jiang; Ke Zhu; Jianqiang Nie; Taobin Liu; Luyao Chen; Wen Deng; Bin Fu; Situ Xiong
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

4.  R.E.N.A.L. Nephrometry Score: A Preoperative Risk Factor Predicting the Fuhrman Grade of Clear-Cell Renal Carcinoma.

Authors:  Shao-Hao Chen; Yu-Peng Wu; Xiao-Dong Li; Tian Lin; Qing-Yong Guo; Ye-Hui Chen; Jin-Bei Huang; Yong Wei; Xue-Yi Xue; Qing-Shui Zheng; Ning Xu
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

5.  Outcomes and predictors of benign histology in patients undergoing robotic partial or radical nephrectomy for renal masses: a multicenter study.

Authors:  Naveen Nandanan; Alessandro Veccia; Alessandro Antonelli; Ithaar Derweesh; Alexandre Mottrie; Andrea Minervini; Monish Aron; Giuseppe Simone; Umberto Capitanio; Claudio Simeone; Daniel Eun; Sisto Perdonà; James Porter; Chandru Sundaram; Chao Zhang; Robert Uzzo; Ben Challacombe; Lance J Hampton; Jihad Kaouk; Francesco Porpiglia; Riccardo Autorino
Journal:  Cent European J Urol       Date:  2020-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.